EVALUATING EOSINOPHILS AS PHARMACODYNAMIC BIOMARKERS OF MEPOLIZUMAB AND RESLIZUMAB FOR PATIENTS WITH EOSINOPHILIC ASTHMA.

被引：0
|
作者：
Gershuny, V. [1 ]
Florian, J. [1 ]
Wang, Y. [1 ]
Strauss, D. [1 ]
机构：
[1] US FDA, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIV-003
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [31] Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
    Walsh, Laura J.
    Casey, Deborah
    Vairamani, Punitha
    Arnott, Fiona
    Plant, Barry J.
    Murphy, Desmond M.
    FRONTIERS IN ALLERGY, 2023, 3
  • [32] Implementation of the FEOS score in patients with severe eosinophilic asthma treated with Reslizumab.
    Liendo Martinez, Katiuska Herminia
    Correa Gutierrez, Crishian Alonso
    Briones Alvarado, Stephany Ivonne
    Mor Martinez, Manuel
    Puente Maestu, Luis
    Garcia De Pedro, Julia
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [33] Impact Of Reslizumab On Healthcare Resource Utilization In Adult Patients With Severe Eosinophilic Asthma
    Wechsler, M. E.
    Korn, S.
    Sun, S. X.
    Garin, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [34] Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
    Brusselle, Guy
    Germinaro, Matthew
    Weiss, Sivan
    Zangrilli, James
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 43 : 39 - 45
  • [35] Meta-Analysis of Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
    Ackert, J. Llanos
    Forshag, M. S.
    Carstens, D.
    Mayer, B.
    Albers, F.
    Liu, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [36] Treatment Response Of Mepolizumab On Health Status And Asthma Control In Patients With Severe Eosinophilic Asthma
    Chupp, G.
    Albers, F. C.
    Nelsen, L. M.
    Bratton, D. J.
    Wang-Jairaj, J.
    Bradford, E.
    Jones, P. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [37] COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE
    Maunoury, F.
    Pribil, C.
    Aubier, M.
    Nachbaur, G.
    Doyle, S.
    VALUE IN HEALTH, 2018, 21 : S413 - S413
  • [38] Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study
    Bulut, Ismet
    Katran, Zeynep Yegin
    Yavuz, Dilek
    Akyildiz, Ali Burkan
    Yakut, Tugce
    Orcen, Cihan
    Mersin, Selver Seda
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2023, 71 (02): : 148 - 155
  • [39] Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab
    Bergantini, Laura
    d'Alessandro, Miriana
    Cameli, Paolo
    Bianchi, Francesco
    Sestini, Piersante
    Bargagli, Elena
    Refini, Rosa Metella
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2020, 181 (10) : 746 - 753
  • [40] Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
    Elneima, Omer
    Ibrahim, Wadah
    Boddy, Claire
    Murphy, Anna
    Bradding, Peter
    Brightling, Christopher
    Siddiqui, Salman
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
12345